Alderley Park, Manchester UK, December 2019 – Today sees the coming together of David D’Alton (D’Alton Kingswell) and Rupert Lewis to form the newco Oyster Venture Partners Ltd. This combination considerably extends the resource and capabilities of the other, combining to become an emerging leader in investment capital raising. OysterVP’s principal mission is to address the long-standing need of emerging entrepreneurs to accelerate their investment processes, typically at both Series-A and -B levels.
“After a number of years in the space, we recognized that fund raising in the health sector is a particular challenge as it always pushing innovation boundaries, requiring investors with deep technical knowledge in the specific vertical within life science.” said Rupert Lewis, Oyster’s CEO and founder. “David and I have developed a methodology and database that we believe will aid with investment fast-tracking, beyond anything else we see in the market.”
OysterVP supports biotechnology, therapeutic, diagnostic, medical device and digital health companies by:
- completing an assessment through its Scientific and Investment Advisory Board;
- raising investment collateral to investor-ready standard;
- qualifying the 100 most closely matched investors from its 10,000+ database;
- completing targeted approaches and a digital marketing campaign;
- qualifying shortlisted responders using all reasonable endeavours to develop interest;
- where relevant making direct investor-client introductions;
The client journey is a fully managed investment seeking process across any combination of the UK, EU, Asia and/or the US/Canada regions. New client-investor introduction are supported along with the developing transaction and to term-sheet development and deal closure where possible.
“Oyster is also an investment advisor to the UK Department for International Trade (DIT Investor Partner).” said David D’Alton, founder and Executive Chairman. “We have developed a close working relationships with government-supported Life Sciences development agencies across the globe, including Finland, Belgium, Israel and South and North Carolina, and private with development partners in Toronto, Connecticut, Beijing, Shanghai and Perth. We are delighted to be working alongside these organisations and the DIT as the fund raising challenge for the early stage life science SME is a global one”.
Oyster has a detailed roadmap over the coming years, where it plans to leverage technology to increase the fund raising programme, as well as developing a team structure that covers the epicenters of life science across the globe.
Alderley Park, Manchester UK, December 2019 – Today sees the coming together of David D’Alton (D’Alton Kingswell) and Rupert Lewis to form the newco Oyster Venture Partners Ltd. This combination considerably extends the resource and capabilities of the other, combining to become an emerging leader in investment capital raising. OysterVP’s principal mission is to address the long-standing need of emerging entrepreneurs to accelerate their investment processes, typically at both Series-A and -B levels.
“After a number of years in the space, we recognized that fund raising in the health sector is a particular challenge as it always pushing innovation boundaries, requiring investors with deep technical knowledge in the specific vertical within life science.” said Rupert Lewis, Oyster’s CEO and founder. “David and I have developed a methodology and database that we believe will aid with investment fast-tracking, beyond anything else we see in the market.”
OysterVP supports biotechnology, therapeutic, diagnostic, medical device and digital health companies by:
- completing an assessment through its Scientific and Investment Advisory Board;
- raising investment collateral to investor-ready standard;
- qualifying the 100 most closely matched investors from its 10,000+ database;
- completing targeted approaches and a digital marketing campaign;
- qualifying shortlisted responders using all reasonable endeavours to develop interest;
- where relevant making direct investor-client introductions;
The client journey is a fully managed investment seeking process across any combination of the UK, EU, Asia and/or the US/Canada regions. New client-investor introduction are supported along with the developing transaction and to term-sheet development and deal closure where possible.
“Oyster is also an investment advisor to the UK Department for International Trade (DIT Investor Partner).” said David D’Alton, founder and Executive Chairman. “We have developed a close working relationships with government-supported Life Sciences development agencies across the globe, including Finland, Belgium, Israel and South and North Carolina, and private with development partners in Toronto, Connecticut, Beijing, Shanghai and Perth. We are delighted to be working alongside these organisations and the DIT as the fund raising challenge for the early stage life science SME is a global one”.
Oyster has a detailed roadmap over the coming years, where it plans to leverage technology to increase the fund raising programme, as well as developing a team structure that covers the epicenters of life science across the globe.